Quality improvement in respiratory care: Decreasing bronchopulmonary dysplasia

Clinics in Perinatology

Volumn 37, Issue 1, 2010, Pages 273-293

  Pfister, Robert H ^a,b   Goldsmith, Jay P ^c,d  

^a UNIVERSITY OF VERMONT   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Quality improvement; Respiratory care

Indexed keywords

BETAMETHASONE; CAFFEINE CITRATE; CORTICOSTEROID; DEXAMETHASONE; LUNG SURFACTANT; METHYLXANTHINE; RETINOL; STEROID;

ABNORMAL LABORATORY RESULT; ACUTE LUNG INJURY; APNEA; ARTIFICIAL VENTILATION; CARDIOMYOPATHY; CEREBRAL PALSY; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; EMPHYSEMA; EVIDENCE BASED PRACTICE; EXTREMELY LOW BIRTH WEIGHT; GASTROINTESTINAL HEMORRHAGE; GESTATIONAL AGE; HEALTH CARE PLANNING; HIGH FREQUENCY OSCILLATION; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHY; HYPOXEMIA; INFANT NUTRITION; INFECTION; LUNG DYSPLASIA; LUNG FIBROSIS; LUNG INJURY; MORBIDITY; MUSCLE HYPERTROPHY; NEONATAL RESPIRATORY DISTRESS SYNDROME; OPTIMAL DRUG DOSE; OXYGEN SATURATION; OXYGEN THERAPY; PATENT DUCTUS ARTERIOSUS; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PREDICTION; PRENATAL CARE; PRIORITY JOURNAL; RESPIRATORY CARE PRACTICE; RESPIRATORY DISTRESS SYNDROME; REVIEW; RISK FACTOR; SENSORY DYSFUNCTION; SYMPTOM; THORAX RADIOGRAPHY; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; TREATMENT OUTCOME; WATER DEPRIVATION;

BRONCHOPULMONARY DYSPLASIA; CHRONIC DISEASE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LUNG DISEASES; QUALITY ASSURANCE, HEALTH CARE; RESPIRATORY THERAPY;

EID: 77950981613     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2010.01.015     Document Type: Review

References (121)

1. Northway W.H., Rosan R.C., Porter D.Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967, 276(7):357-368.
2. Walsh M.C., Wilson-Costello D., Zadell A., et al. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003, 23(6):451-456.
3. Charafeddine L., D'Angio C.T., Phelps D.L. Atypical chronic lung disease patterns in neonates. Pediatrics 1999, 103(4 Pt 1):759-765.
4. Jobe A.H., Bancalari E. NICHD/NHLBI/ORD workshop summary: bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001, 163:1723-1729.
5. Bancalari E. Changes in the pathogenesis and prevention of chronic lung disease of prematurity. Am J Perinatol 2001, 18(1):1-9.
6. Jobe A.H., Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998, 53(1):81-94.
7. Hack M., Wilson-Costello D., Friedman H., et al. Neurodevelopment and predictors of outcomes of children with birth weights of less than 1000 g: 1992-1995. Arch Pediatr Adolesc Med 2000, 154(7):725-731.
8. Hoekstra R.E., Ferrara T.B., Couser R.J., et al. Survival and long-term neurodevelopmental outcome of extremely premature infants born at 23-26 weeks' gestational age at a tertiary center. Pediatrics 2004, 113(1 Pt 1):e1-e6.
9. Tyson J.E., Parikh N.A., Langer J., et al. Intensive care for extreme prematurity-moving beyond gestational age. N Engl J Med 2008, 358(16):1672-1681.
10. Bryan M.H., Hardie M.J., Reilly B.J., et al. Pulmonary function studies during the first year of life in infants recovering from the respiratory distress syndrome. Pediatrics 1973, 52(2):169-178.
11. Wolfson M.R., Bhutani V.K., Shaffer T.H., et al. Mechanics and energetics of breathing helium in infants with bronchopulmonary dysplasia. J Pediatr 1984, 104(5):752-757.
12. Tepper R.S., Morgan W.J., Cota K., et al. Expiratory flow limitation in infants with bronchopulmonary dysplasia. J Pediatr 1986, 109(6):1040-1046.
13. Mourani P.M., Ivy D.D., Gao D., et al. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2004, 170(9):1006-1013.
14. Goodman G., Perkin R.M., Anas N.G., et al. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr 1988, 112(1):67-72.
15. Kinsella J.P., Greenough A., Abman S.H. Bronchopulmonary dysplasia. Lancet 2006, 367(9520):1421-1431.
16. Kraybill E.N., Runyan D.K., Bose C.L., et al. Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams. J Pediatr 1989, 115(1):115-120.
17. Bjorklund L.J., Ingimarsson J., Curstedt T., et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997, 42(3):348-355.
18. Munshi U.K., Niu J.O., Siddiq M.M., et al. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol 1997, 24(5):331-336.
19. Pierce M.R., Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol 1995, 19(6):371-378.
20. Groneck P., Speer C.P. Inflammatory mediators and bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed 1995, 73(1):F1-F3.
21. Ozdemir A., Brown M.A., Morgan W.J. Markers and mediators of inflammation in neonatal lung disease. Pediatr Pulmonol 1997, 23(4):292-306.
22. Nickerson B.G., Taussig L.M. Family history of asthma in infants with bronchopulmonary dysplasia. Pediatrics 1980, 65(6):1140-1144.
23. Clark D.A., Pincus L.G., Oliphant M., et al. HLA-A2 and chronic lung disease in neonates. JAMA 1982, 248(15):1868-1869.
24. Wright L.L., Verter J., Younes N., et al. Antenatal corticosteroid administration and neonatal outcome in very low birth weight infants: the NICHD Neonatal Research Network. Am J Obstet Gynecol 1995, 173(1):269-274.
25. Roberts D., Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006, (3). CD004454.
26. Horbar J.D. Antenatal corticosteroid treatment and neonatal outcomes for infants 501 to 1500 gm in the Vermont-Oxford Trials Network. Am J Obstet Gynecol 1995, 173(1):275-281.
27. Young T.E., Kruyer L.S., Marshall D.D., et al. Population-based study of chronic lung disease in very low birth weight infants in North Carolina in 1994 with comparisons with 1984. The North Carolina Neonatologists Association. Pediatrics 1999, 104(2):e17.
28. Marshall D.D., Kotelchuck M., Young T.E., et al. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999, 104(6):1345-1350.
29. Rojas M.A., Gonzalez A., Bancalari E., et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995, 126(4):605-610.
30. Avery M.E., Tooley W.H., Keller J.B., et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 1987, 79(1):26-30.
31. Van Marter L.J., Allred E.N., Pagano M., et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 2000, 105(6):1194-1201.
32. Lenfant C. Shattuck lecture. Clinical research to clinical practice-lost in translation?. N Engl J Med 2003, 349(9):868-874.
33. Gray J.A.M. Evidence-based healthcare 2001, Edinburgh, Churchill Livingston, New York, p. xxix, 444. 2nd edition.
34. Center_for_Evidence_Based_Medicine Available at:, Accessed January 8, 2010. http://www.cebm.net/index.aspx?o=1025.
35. American Heart Association ILCOR, c2010 evidence evaluation worksheet guidelines Available at:, Accessed January 8, 2010. http://www.americanheart.org/ILCOR.
36. Shenai J.P., Chytil F., Jhaveri A., et al. Plasma vitamin A and retinol-binding protein in premature and term neonates. J Pediatr 1981, 99(2):302-305.
37. Darlow B.A., Graham P.J. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007, (4). CD000501.
38. Tyson J.E., Wright L.L., Oh W., et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999, 340(25):1962-1968.
39. Ambalavanan N., Wu T.J., Tyson J.E., et al. A comparison of three vitamin A dosing regimens in extremely-low-birth-weight infants. J Pediatr 2003, 142(6):656-661.
40. Soll R.F., Morley C.J. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001, (2). CD000510.
41. Yost C.C., Soll R.F. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2000, (2). CD001456.
42. Jobe A.H. Antenatal factors and the development of bronchopulmonary dysplasia. Semin Neonatol 2003, 8(1):9-17.
43. Feldman D.M., Carbone J., Belden L., et al. Betamethasone vs dexamethasone for the prevention of morbidity in very-low-birthweight neonates. Am J Obstet Gynecol 2007, 197(3):284. e1-4.
44. Lee B.H., Stoll B.J., McDonald S.A., et al. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics 2006, 117(5):1503-1510.
45. Askie L.M., Henderson-Smart D.J., Irwig L., et al. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003, 349(10):959-967.
46. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000, 105(2):295-310.
47. Ambalavanan N., Carlo W.A. Ventilatory strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 2006, 30(4):192-199.
48. Hagadorn J.I., Furey A.M., Nghiem T.H., et al. Achieved versus intended pulse oximeter saturation in infants born less than 28 weeks' gestation: the AVIOx study. Pediatrics 2006, 118(4):1574-1582.
49. Goldsmith J.P., Greenspan J. NICU oxygen management: a team effort. Pediatrics 2007, 119(6):1195-1196.
50. Palta M., Gabbert D., Weinstein M.R., et al. Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. The Newborn Lung Project. J Pediatr 1991, 119(2):285-292.
51. Clark R.H., Gerstmann D.R., Jobe A.H., et al. Lung injury in neonates: causes, strategies for prevention, and long-term consequences. J Pediatr 2001, 139(4):478-486.
52. Garland J.S., Buck R.K., Allred E.N., et al. Hypocarbia before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome. Arch Pediatr Adolesc Med 1995, 149(6):617-622.
53. Dreyfuss D., Saumon G. Barotrauma is volutrauma, but which volume is the one responsible?. Intensive Care Med 1992, 18(3):139-141.
54. Taskar V., John J., Evander E., et al. Surfactant dysfunction makes lungs vulnerable to repetitive collapse and reexpansion. Am J Respir Crit Care Med 1997, 155(1):313-320.
55. Attar M.A., Donn S.M. Mechanisms of ventilator-induced lung injury in premature infants. Semin Neonatol 2002, 7(5):353-360.
56. Ehlert C.A., Truog W.E., Thibeault D.W., et al. Hyperoxia and tidal volume: Independent and combined effects on neonatal pulmonary inflammation. Biol Neonate 2006, 90(2):89-97.
57. Greisen G., Vannucci R.C. Is periventricular leucomalacia a result of hypoxic-ischaemic injury? Hypocapnia and the preterm brain. Biol Neonate 2001, 79(3-4):194-200.
58. Fabres J., Carlo W.A., Phillips V., et al. Both extremes of arterial carbon dioxide pressure and the magnitude of fluctuations in arterial carbon dioxide pressure are associated with severe intraventricular hemorrhage in preterm infants. Pediatrics 2007, 119(2):299-305.
59. Mariani G., Cifuentes J., Carlo W.A. Randomized trial of permissive hypercapnia in preterm infants. Pediatrics 1999, 104(5 Pt 1):1082-1088.
60. Carlo W.A., Stark A.R., Wright L.L., et al. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J Pediatr 2002, 141(3):370-374.
61. Keszler M. Volume-targeted ventilation. J Perinatol 2005, 25(Suppl 2):S19-S22.
62. McCallion N., Davis P.G., Morley C.J. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev 2005, (3). CD003666.
63. Greenough A., Milner A.D., Dimitriou G. Synchronized mechanical ventilation for respiratory support in newborn infants. Cochrane Database Syst Rev 2001, (1). CD000456.
64. Jobe A.H., Kramer B.W., Moss T.J., et al. Decreased indicators of lung injury with continuous positive expiratory pressure in preterm lambs. Pediatr Res 2002, 52(3):387-392.
65. Verder H., Albertsen P., Ebbesen F., et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics 1999, 103(2):E24.
66. Davis P.G., Henderson-Smart D.J. Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants. Cochrane Database Syst Rev 2003, (2). CD000143.
67. Davis P.G., Lemyre B., de Paoli A.G. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev 2001, (3). CD003212.
68. Henderson-Smart D.J., Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev 2001, (3). CD000140.
69. Schmidt B., Roberts R.S., Davis P., et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006, 354(20):2112-2121.
70. Courtney S.E., Durand D.J., Asselin J.M., et al. High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants. N Engl J Med 2002, 347(9):643-652.
71. Johnson A.H., Peacock J.L., Greenough A., et al. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med 2002, 347(9):633-642.
72. Henderson-Smart D.J., Cools F., Bhuta T., et al. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 2007, (3). CD000104.
73. Thome U.H., Carlo W.A., Pohlandt F. Ventilation strategies and outcome in randomised trials of high frequency ventilation. Arch Dis Child Fetal Neonatal Ed 2005, 90(6):F466-F473.
74. Ammari A., Suri M., Milisavljevic V., et al. Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr 2005, 147(3):341-347.
75. De Klerk A.M., De Klerk R.K. Nasal continuous positive airway pressure and outcomes of preterm infants. J Paediatr Child Health 2001, 37(2):161-167.
76. Gittermann M.K., Fusch C., Gittermann A.R., et al. Early nasal continuous positive airway pressure treatment reduces the need for intubation in very low birth weight infants. Eur J Pediatr 1997, 156(5):384-388.
77. Jonsson B., Katz-Salamon M., Faxelius G., et al. Neonatal care of very-low-birthweight infants in special-care units and neonatal intensive-care units in Stockholm. Early nasal continuous positive airway pressure versus mechanical ventilation: gains and losses. Acta Paediatr Suppl 1997, 419:4-10.
78. Kamper J., Wulff K., Larsen C., et al. Early treatment with nasal continuous positive airway pressure in very low-birth-weight infants. Acta Paediatr 1993, 82(2):193-197.
79. Thomson M.A. Continuous positive airway pressure and surfactant; combined data from animal experiments and clinical trials. Biol Neonate 2002, 81(Suppl 1):16-19.
80. Morley C.J., Davis P.G., Doyle L.W., et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008, 358(7):700-708.
81. Stevens T.P., Harrington E.W., Blennow M., et al. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007, (4). CD003063.
82. Ingimarsson J., Björklund L.J., Curstedt T., et al. Incomplete protection by prophylactic surfactant against the adverse effects of large lung inflations at birth in immature lambs. Intensive Care Med 2004, 30(7):1446-1453.
83. Bennett S., Finer N.N., Rich W., et al. A comparison of three neonatal resuscitation devices. Resuscitation 2005, 67(1):113-118.
84. Cotton R.B., Stahlman M.T., Kovar I., et al. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr 1978, 92(3):467-473.
85. Clyman R.I. Mechanisms regulating the ductus arteriosus. Biol Neonate 2006, 89(4):330-335.
86. Chorne N., Leonard C., Piecuch R., et al. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 2007, 119(6):1165-1174.
87. Kavvadia V., Greenough A., Dimitriou G., et al. Randomised trial of fluid restriction in ventilated very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2000, 83(2):F91-F96.
88. Hartnoll G., Betremieux P., Modi N. Randomised controlled trial of postnatal sodium supplementation on oxygen dependency and body weight in 25-30 week gestational age infants. Arch Dis Child Fetal Neonatal Ed 2000, 82(1):F19-F23.
89. Bell E.F., Acarregui M.J. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2008, (1). CD000503.
90. Oh W., Poindexter B.B., Perritt R., et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005, 147(6):786-790.
91. Kavvadia V., Greenough A., Dimitriou G., et al. Randomized trial of two levels of fluid input in the perinatal period-effect on fluid balance, electrolyte and metabolic disturbances in ventilated VLBW infants. Acta Paediatr 2000, 89(2):237-241.
92. Stoll B.J., Hansen N., Fanaroff A.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002, 110(2 Pt 1):285-291.
93. Liljedahl M., Bodin L., Schollin J. Coagulase-negative staphylococcal sepsis as a predictor of bronchopulmonary dysplasia. Acta Paediatr 2004, 93(2):211-215.
94. Polin R.A., Polin R.A., Yoder M.C. Workbook in practical neonatology 2007, Saunders/Elsevier, Philadelphia, p. xii, 500. 4th edition.
95. Yoder M.C., Chua R., Tepper R. Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia. Am Rev Respir Dis 1991, 143(5 Pt 1):1044-1048.
96. Halliday H.L. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate 1999, 76(Suppl 1):29-40.
97. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009, (1). CD001146.
98. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009, (1). CD001145.
99. Jobe A.H., Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001, 163(7):1723-1729.
100. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004, 114(6):1649-1657.
101. Tin W., Wiswell T.E. Adjunctive therapies in chronic lung disease: examining the evidence. Semin Fetal Neonatal Med 2008, 13(1):44-52.
102. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002, 109(2):330-338.
103. Shah V., Ohlsson A., Halliday H.L., et al. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2007, (4). CD001969.
104. Shah S.S., Ohlsson A., Halliday H., et al. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2007, (4). CD002057.
105. Cole C.H., Colton T., Shah B.L., et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999, 340(13):1005-1010.
106. Burch K., Rhine W., Baker R., et al. Implementing potentially better practices to reduce lung injury in neonates. Pediatrics 2003, 111(4 Pt 2):e432-e436.
107. Plsek P.E. Quality improvement methods in clinical medicine. Pediatrics 1999, 103(1 Suppl E):203-214.
108. Shine K.I. Health care quality and how to achieve it. Acad Med 2002, 77(1):91-99.
109. Shewhart W.A. Economic control of quality of manufactured product 1931, D. Van Nostrand Company, Inc, New York, p. xiv, 501.
110. Horbar J.D., Rogowski J., Plsek P.E., et al. Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network. Pediatrics 2001, 107(1):14-22.
111. Sharek P.J., Baker R., Litman F., et al. Evaluation and development of potentially better practices to prevent chronic lung disease and reduce lung injury in neonates. Pediatrics 2003, 111(4 Pt 2):e426-e431.
112. Kaempf J.W., Campbell B., Sklar R.S., et al. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams. Pediatrics 2003, 111(4 Pt 2):e534-e541.
113. Payne N.R., LaCorte M., Sun S., et al. Evaluation and development of potentially better practices to reduce bronchopulmonary dysplasia in very low birth weight infants. Pediatrics 2006, 118(Suppl 2):S65-S72.
114. Payne N.R., LaCorte M., Karna P., et al. Reduction of bronchopulmonary dysplasia after participation in the Breathsavers Group of the Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. Pediatrics 2006, 118(Suppl 2):S73-S77.
115. Birenbaum H.J., Dentry A., Cirelli J., et al. Reduction in the incidence of chronic lung disease in very low birth weight infants: results of a quality improvement process in a tertiary level neonatal intensive care unit. Pediatrics 2009, 123(1):44-50.
116. Nowadzky T., Pantoja A., Britton J.R. Bubble continuous positive airway pressure, a potentially better practice, reduces the use of mechanical ventilation among very low birth weight infants with respiratory distress syndrome. Pediatrics 2009, 123(6):1534-1540.
117. Horbar J.D., Carpenter J.H., Buzas J., et al. Collaborative quality improvement to promote evidence based surfactant for preterm infants: a cluster randomised trial. BMJ 2004, 329(7473):1004.
118. Walsh M., Laptook A., Kazzi S.N., et al. A cluster-randomized trial of benchmarking and multimodal quality improvement to improve rates of survival free of bronchopulmonary dysplasia for infants with birth weights of less than 1250 grams. Pediatrics 2007, 119(5):876-890.
119. Lee S.K., Aziz K., Singhal N., et al. Improving the quality of care for infants: a cluster randomized controlled trial. CMAJ 2009, 181(8):469-476.
120. Shojania K.G., Ranji S.R., McDonald K.M., et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA 2006, 296(4):427-440.
121. Berwick D.M. The science of improvement. JAMA 2008, 299(10):1182-1184.